Photodiagnosis and photodynamic therapy · 2025
Comparison of efficacy of ALA-PDT and CO2 laser in the treatment of vaginal intraepithelial neoplasia II (VaIN II).
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ji Huixiang, Xia Yufang, Cai Huihui, Ding Zhaoxia, Guo Hailong, Liu Hui, Lou Yanhui
Аннотация
OBJECTIVE: To compare and analyze the efficacy as well as adverse effects of 5-aminolevulinic acid photodynamic therapy (5-ALA-PDT) and carbon dioxide (CO₂) laser therapy in the treatment of vaginal intraepithelial neoplasia II (VaIN II), and assess the feasibility, safety, and influencing factors of ALA-PDT.
METHODS: A retrospective review was conducted on the clinical data of 79 patients with VaIN II (PDT group = 37, Laser group = 42) who were treated at the Gynecology Department of the Affiliated Hospital of Qingdao University from January 2022 to January 2024. Follow-up evaluations were carried out at 3, 6, and 12 months after treatment. During these follow-ups, human papillomavirus (HPV) testing, cervical liquid-based cytology (TCT), colposcopy, and vaginal lesion biopsy were utilized to assess key outcomes, including the lesion reversal rate, HPV clearance, and treatment-related adverse reactions in both groups.
RESULTS: The lesion reversal rates following ALA-PDT treatment were 83.3 %, 86.1 %, and 88.2 % at 3, 6, and 12 months, respectively. There was no significant difference when compared to the laser group. However, the negative HPV conversion rates at 6 and 12 months after ALA-PDT treatment were 73.5 % and 87.5 %, respectively, which were significantly higher than those observed in the CO2 laser group (P < 0.05). Adverse events related to photodynamic therapy occurred in 13.5 % (5/37) of the cases, which was significantly lower than the 35.7 % (15/42) in the laser group. In the laser group, increased incidences of vaginal bleeding and scarring were observed. Logistic univariate regression analysis revealed that factors such as a disease duration of >1 year, multifocal lesions, and a history of cervical cancer or precancerous surgery negatively influenced lesion reversal at 6 months after ALA-PDT treatment (P < 0.05). Additionally, factors like patient age over 50 years old (menopause), having more than two pregnancies, an imbalance in the vaginal microbiota, a prolonged HPV infection (lasting >1 year), and HPV superinfection affected HPV clearance at 6 months after ALA-PDT treatment (P < 0.05).
CONCLUSION: For the treatment of VaIN II, ALA-PDT exhibits equivalent lesion reversal rates and superior HPV clearance compared to CO2 laser treatment, while causing minimal anatomical disruption to the vaginal tissue.
METHODS: A retrospective review was conducted on the clinical data of 79 patients with VaIN II (PDT group = 37, Laser group = 42) who were treated at the Gynecology Department of the Affiliated Hospital of Qingdao University from January 2022 to January 2024. Follow-up evaluations were carried out at 3, 6, and 12 months after treatment. During these follow-ups, human papillomavirus (HPV) testing, cervical liquid-based cytology (TCT), colposcopy, and vaginal lesion biopsy were utilized to assess key outcomes, including the lesion reversal rate, HPV clearance, and treatment-related adverse reactions in both groups.
RESULTS: The lesion reversal rates following ALA-PDT treatment were 83.3 %, 86.1 %, and 88.2 % at 3, 6, and 12 months, respectively. There was no significant difference when compared to the laser group. However, the negative HPV conversion rates at 6 and 12 months after ALA-PDT treatment were 73.5 % and 87.5 %, respectively, which were significantly higher than those observed in the CO2 laser group (P < 0.05). Adverse events related to photodynamic therapy occurred in 13.5 % (5/37) of the cases, which was significantly lower than the 35.7 % (15/42) in the laser group. In the laser group, increased incidences of vaginal bleeding and scarring were observed. Logistic univariate regression analysis revealed that factors such as a disease duration of >1 year, multifocal lesions, and a history of cervical cancer or precancerous surgery negatively influenced lesion reversal at 6 months after ALA-PDT treatment (P < 0.05). Additionally, factors like patient age over 50 years old (menopause), having more than two pregnancies, an imbalance in the vaginal microbiota, a prolonged HPV infection (lasting >1 year), and HPV superinfection affected HPV clearance at 6 months after ALA-PDT treatment (P < 0.05).
CONCLUSION: For the treatment of VaIN II, ALA-PDT exhibits equivalent lesion reversal rates and superior HPV clearance compared to CO2 laser treatment, while causing minimal anatomical disruption to the vaginal tissue.